Inhibition of growth hormone excess reduces insulin resistance and ovarian dysfunction in a lean case of polycystic ovary syndrome with a growth-hormone-producing pituitary adenoma

Horm Res. 2003;59(3):149-55. doi: 10.1159/000069064.

Abstract

A 23-year-old female with polycystic ovary syndrome (PCOS) and a growth-hormone (GH)-producing pituitary adenoma is described. A reduction in the elevated GH levels to normal levels following the administration of dopaminergic agents decreased plasma insulin-like growth factor (IGF)-1 and ovarian dysfunction. Menstrual cycles were therefore restored and the number of ovarian cysts reduced, suggesting that insulin and/or IGF-1, stimulators of theca cell proliferation, may be pathogenetic factors in PCOS.

Publication types

  • Case Reports

MeSH terms

  • Acanthosis Nigricans / complications
  • Acromegaly / complications
  • Adenoma / metabolism*
  • Adult
  • Bromocriptine / therapeutic use
  • Dopamine Agents / therapeutic use
  • Female
  • Glucose Tolerance Test
  • Human Growth Hormone / antagonists & inhibitors*
  • Human Growth Hormone / biosynthesis*
  • Humans
  • Insulin / physiology
  • Insulin Resistance / physiology*
  • Insulin-Like Growth Factor I / physiology
  • Lisuride / analogs & derivatives*
  • Lisuride / therapeutic use
  • Magnetic Resonance Imaging
  • Menstrual Cycle / drug effects
  • Ovary / pathology
  • Ovary / physiopathology*
  • Pancreatic Function Tests
  • Pituitary Function Tests
  • Pituitary Neoplasms / metabolism*
  • Polycystic Ovary Syndrome / drug therapy
  • Polycystic Ovary Syndrome / pathology
  • Polycystic Ovary Syndrome / physiopathology*
  • Theca Cells / physiology

Substances

  • Dopamine Agents
  • Insulin
  • Human Growth Hormone
  • dironyl
  • Bromocriptine
  • Insulin-Like Growth Factor I
  • Lisuride